quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·2d
PRRelease
Rezolute Inc. logo

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

RZLT· Rezolute Inc.
Health Care
Original source

Companies

  • RZLT
    Rezolute Inc.
    Health Care

Recent analyst ratings

  • Mar 25UpdateWedbush$5.00
  • Dec 11UpdateCraig Hallum$2.00
  • Dec 11UpdateCantor Fitzgerald-
  • Dec 11UpdateWedbush$1.00
  • Nov 5UpdateWedbush$12.00
  • Aug 27UpdateGuggenheim$11.00

Related

  • INSIDER23d
    SEC Form 4 filed by Evans Daron
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Rezolute Inc.
  • ANALYST29d
    Rezolute upgraded by Wedbush with a new price target
  • SEC30d
    Rezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR30d
    Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
  • INSIDER50d
    Chief Medical Officer Roberts Brian Kenneth covered exercise/tax liability with 11,439 shares, decreasing direct ownership by 4% to 296,913 units (SEC Form 4)
  • INSIDER50d
    CFO Evans Daron covered exercise/tax liability with 11,438 shares, decreasing direct ownership by 3% to 404,462 units (SEC Form 4)
  • INSIDER50d
    CEO Elam Nevan C covered exercise/tax liability with 27,618 shares, decreasing direct ownership by 4% to 613,501 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022